CareDx (CDNA)
(Delayed Data from NSDQ)
$31.54 USD
+0.58 (1.87%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $31.55 +0.01 (0.03%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth A Momentum B VGM
Price, Consensus and EPS Surprise
CDNA 31.54 +0.58(1.87%)
Will CDNA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CDNA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CDNA
CareDx, Inc. (CDNA) Hit a 52 Week High, Can the Run Continue?
CareDx (CDNA) Upgraded to Strong Buy: What Does It Mean for the Stock?
CDNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Compared to Estimates, CareDx (CDNA) Q2 Earnings: A Look at Key Metrics
CareDx (CDNA) Q2 Earnings and Revenues Beat Estimates
CareDx (CDNA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Other News for CDNA
What 4 Analyst Ratings Have To Say About CareDx
Apple, Lineage, OneStream initiated: Wall Street's top analyst calls
Positive Outlook for CareDx: Anticipating Revenue Growth and Manageable Legal Challenges
CareDx upgraded to Buy from Neutral at BTIG ahead of analyst day
BTIG gets more bullish on CareDx, upgrades shares